Project of Latvian WHO Collaborating Centre for Research and Training in Management of Multidrug-Resistant Tuberculosis (MDR-TB) was started in the year 1999 as a cooperation project of State Agency of Tuberculosis and Lung Disease with the Centre for Disease Control and Prevention and the University of Arkansas for Medical Sciences. Latvian National Tuberculosis program established an International Training Centre (ITC), which was devoted to the treatment and management of MDR-TB.
ABOUT US
The objectives of the ICT are to provide high quality, evidence-based capacity development at all levels (individual, organizational and institutional), drawing on worldwide evidence and in line with the latest developments and WHO guidance.
With these objectives being met, in November 2004, WHO honored the ITC by awarding it the prestigious status of a WHO Collaborating Centre. Capacity development activities are structured according to the latest scientific developments in practical aspects of the treatment and management of DR-TB.
At present WHO CC Latvia is a structural part of the Tuberculosis and Lung Diseases Centre of Riga East University hospital. Administrative work of WHO CC Latvia is carried out in collaboration with NGO Latvian Society against Tuberculosis. The faculty of WHO CC involves more than 20 experts, clinicians, scientists. WHO CC Latvia regularly cooperates with international organizations and projects to engage in training activities experts from the field and provide high-level, evidence-based up-to-date training.
Terms of Reference of the WHO CC Latvia
In collaboration with the WHO HQ and WHO Regional Office for Europe to provide up-to-date, high-quality, evidence-based training and education for health care workers to successfully implement and sustain the key challenges in TB control of the End TB Strategy.
To collaborate with the WHO Working Group on MDR-TB, promote the implementation of WHO guidelines of the MDR-TB strategies through consultations and technical assistance to National TB Programmes, in line with End TB Strategy and Regional policy frameworks.
To participate in collaborative research under WHO leadership on new TB drug development and laboratory diagnostic methods, in line with End TB strategy and Regional policy frameworks.
Under WHO guidance to share the WHO CC`s experience with the TB community in the Region, in line with End TB strategy and Regional policy frameworks.
